Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This case report observed that applying "Kadi" herbal oils three times daily led to rapid wound healing and excellent cosmetic outcomes in a 10-year-old boy with a deep partial-thickness burn, highlighting "Kadi" as a promising treatment that deserves further investigation through randomized controlled trials.

Baricitinib effectively promotes beard regrowth in most men with alopecia areata universalis.

In this prospective study, ritlecitinib effectively reduced hair loss in patients with severe alopecia areata, with 43.3% of participants achieving a 20 or lower SALT score by week 24, and showed a good midterm safety profile.

In this laboratory study, the researchers reported that an ethnomedicinal hair growth formula from East Nusa Tenggara, incorporating Kemiri, Kembang sepatu, Beringin, Mangkokan, and Waru, demonstrated significant antioxidant activity and effectively stimulated hair growth, suggesting potential development as a natural cosmeceutical.

This study found that the highest antioxidant-activity formulation of the RENTT herbal combination effectively stimulated hair growth in mice and may serve as a natural therapy for chemotherapy-induced alopecia.

This source describes vitiligo as a chronic condition marked by the loss of skin pigmentation and discusses leukotrichia, a feature affecting 10% to 60% of cases, which arises from melanocyte loss in hair follicles and appears as well-defined white patches on the skin.

This study found that an optimal combination of ethnomedicinal extracts from East Nusa Tenggara, Indonesia, significantly increased hair length in mice, suggesting potential as a natural agent for hair growth through antioxidant mechanisms.

This study concluded that the combination 3 of the Nusa Tenggara Timur Ethnomedicinal Formula shows strong antioxidant activity and significantly increases hair follicle thickness in a chemotherapy-induced alopecia model in mice.

In this study, researchers developed an optimized formulation of a traditional ethnomedicinal recipe from East Nusa Tenggara, which demonstrated strong antioxidant activity and significantly enhanced hair growth in a mouse alopecia model, compared to control groups.

Results are not reported in this abstract, which notes that while Janus kinase inhibitors like baricitinib show therapeutic benefits for alopecia areata, the mechanisms and reliable predictors of response remain unclear.

In this study, baricitinib, a JAK inhibitor, was found to significantly improve scalp hair regrowth in both adults and adolescents with severe alopecia areata, with many achieving nearly full regrowth by weeks 36 or 52.

In this study, 49% of patients with alopecia areata achieved a significant response to baricitinib, with a lower baseline severity, shorter disease duration, and longer treatment duration identified as significant predictors of treatment success.

In this study, a possible case of Wolf’s isotopic response was observed, where a 72-year-old woman developed superficial basal cell carcinoma at a prior herpes zoster site on her scalp, possibly due to altered local immunity from the zoster episode.

This study found that dietary serine levels influence hair follicle stem cells' ability to balance hair regeneration and wound repair, offering insights for potential interventions to accelerate wound healing.

This study at NYU Langone Health suggests that younger patients with androgenetic alopecia may experience greater improvements in hair density with PRP treatment compared to older patients, who might need more sessions for similar results.

This study examined the safety profile of ritlecitinib, a drug for alopecia areata, and found that it does not cause significant QTc prolongation or severe lymphopenia, with no unique safety risks expected in adolescents.

Photobiomodulation did not significantly improve hair density in dogs with alopecia X.

This study found that elevated luteinizing hormone levels were significantly associated with female pattern hair loss, and implicated LH/LHR signaling in the aging and damage of hair follicles.

This study highlights the role of immune dysregulation, microRNA modulation, and SIRT1 pathways in alopecia areata, suggesting antisense oligonucleotides targeting miR-485-3p as a promising therapeutic strategy for promoting hair regrowth and reducing inflammation in murine models.

In this study at Tohoku University Hospital, 41% of severe alopecia areata patients achieved significant hair regrowth with baricitinib treatment over 9 months, with predictors of better outcomes including shorter disease duration, female sex, initial mild disease, certain alopecia types, and prior IVMP therapy.

This study of baricitinib in adults with severe alopecia areata found that after initial success, 10.9% of participants lost treatment response by Week 152. Factors like longer disease duration and severe baseline symptoms were more common in those losing response.

This case report details a rare instance of a young male with coexisting autoimmune polyendocrine syndrome type 2 and anti-GAD65 antibody-associated stiff person syndrome, where symptoms improved by adding intravenous immunoglobulin therapy, emphasizing the importance of awareness for early diagnosis and treatment.

This prospective observational study investigated 200 patients with non-scarring alopecia, concluding that accurate classification combined with individualized treatment, including combination therapies, significantly improved outcomes over monotherapy with topical minoxidil.

In this pilot randomized clinical trial, TRT combined with finasteride increased lean mass, muscle size, and bone mineral density without prostate enlargement in men with spinal cord injury, suggesting potential benefits for body composition and musculoskeletal health.

This study found that recombinant human ADM2 treatment inhibited cell proliferation and induced apoptosis in human hair follicles, contrasting with the previously documented pro-proliferative and anti-apoptotic functions of ADM2.

In this study, patients with severe alopecia areata treated with baricitinib showed continued improvement in scalp hair regrowth from weeks 52 to 152, particularly among those initially responding with eyelash or eyebrow regrowth but not scalp hair, with 39% achieving substantial regrowth by week 104.

Eyebrow and eyelash regrowth usually matches scalp hair response in alopecia areata patients treated with baricitinib.

This study found that inhibiting the Mitochondrial Pyruvate Carrier in human scalp hair follicles caused metabolic stress that halted cell proliferation and disrupted key signaling pathways, with these effects partially reversed by an integrated stress response inhibitor.